ProBioGen Partners With ImmunOs Therapeutics To Deliver Innovative Therapy For Cancer Patients

The agreement between ProBioGen and ImmunOs Therapeutics has been extended in order to continue producing clinical materials on a wide scale for IOS-1002, ImmunOs' main initiative for the treatment of cancer. For the novel biologic created by ImmunOs, ProBioGen first produced the cell line, the manufacturing technique, and the initial clinical material. "We at ImmunOs are very satisfied with the work done by ProBioGen. We highly appreciate the collaborative partnership with ProBioGen and the team's dedication and solution orientation.

The tireless effort of the ProBioGen team has enabled ImmunOs to start clinical development as planned and to meet our milestones," said Jeff Abbey, chief operating officer of ImmunOs Therapeutics. "Partnership is one of our core values, as it is key in working successfully together. With this in mind we are confident that our continuous collaboration is based on mutual trust and reliability," said Dr. René Brecht, chief operations officer of ProBioGen.

First-in-class medicines for the treatment of cancer and autoimmune illnesses are being developed by ImmunOs medicines using its HLA-based technological platform. ProBioGen is a company with headquarters in Berlin that specialises in the development and production of viral vectors, vaccines, and active compounds used in biopharmaceuticals.